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Abstract
Background: Tiotropium is reimbursed since March 2004 in Belgium for the treatment of Chronic Obstructive
Pulmonary Disease (COPD). Questions however remain on this product’s value for money. The purpose of this
study is to calculate tiotropium’s cost-effectiveness under real-world conditions.
Methods: Strengths of both observational and RCT data were combined in a model. A large longitudinal (2002-
2006) observational dataset of regular tiotropium users (56 321 patients) was analysed to retrieve the baseline risk
for exacerbations and exacerbation-related hospitalisations the year before the first delivery of tiotropium. The
relative treatment effect from the UPLIFT (Understanding Potential Long-term Impacts on Function with
Tiotropium) trial was then applied to this baseline risk to reflect the effect of tiotropium treatment and calculate
the intervention’s incremental cost-effectiveness ratio (ICER).
Results: After 1000 Latin Hypercube simulations, the incremental benefit expressed as quality-adjusted life years
(QALY) gained is on average 0.00048 (95% confidence interval (CI) 0.00009 - 0.00092). In combination with a
substantial mean incremental cost of €373 per patient (95% CI 279 - 475), this results in an unfavourable average
ICER of €1 244 023 (95% CI 328 571 - 4 712 704) per QALY gained. Results were most sensitive to the treatment
effect on hospitalisations. Based on our large observational database, up to 89% of the patients were not
hospitalised for COPD in the year before the first tiotropium delivery.
Conclusions: The main cause for tiotropium’s unfavourable cost-effectiveness ratio is a combination of a relative
high price for tiotropium, a low number of hospitalisations without tiotropium treatment (on average 0.14/year)
and a non-significant treatment effect (on average 0.94) with respect to avoiding exacerbation-related
hospitalisations. From an economic point of view, a revision of reimbursement modalities (e.g. with a lower price)
would be justified and would entail a more efficient use of resources.
Background
Tiotropium (Spiriva®, Boehringer-Ingelheim) is a once-
daily inhaled long-acting bronchodilator of the anticholi-
nergic class, used for the maintenance treatment of
Chronic Obstructive Pulmonary Disease (COPD). In
Belgium, tiotropium is reimbursed since March 1, 2004.
This decision was partly based on the claims that the
budget impact for the National Institute for Health and
Disability Insurance (NIHDI) would be offset by cost
savings due to less hospital admissions and less use of
antibiotics and oral corticosteroids. Being a Class I drug,
i.e. a drug with an assumed therapeutic added value in
comparison to existing alternatives, a revision of the
reimbursement decision was required within 36 months.
The conclusions of this revision indicated that there was
no benefit of using tiotropium in comparison to long-
acting b2-agonists, that the price of tiotropium was
higher than these alternatives, and that there was no evi-
dence of the introduction of tiotropium decreasing
treatment costs related to other drugs [1]. Nevertheless,
reimbursement modalities remained unchanged after
this revision. Since then, results of the large UPLIFT
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which are taken into account in this economic
evaluation.
In Belgium, with a total population of about 10.6 mil-
lion inhabitants, NIHDI reimbursements for tiotropium
were more than €26 million in 2007 for 86 000 patients
with at least one delivery of tiotropium. One month of
tiotropium costs €51.75 per patient, whereas e.g. salme-
terol, i.e. another long-acting bronchodilator, costs
€31.24 per month.
The goal of this study, part of a full Health Technol-
ogy Assessment (HTA) report performed by the inde-
pendent Belgian Health Care Knowledge Centre, [2] is
to calculate the cost-effectiveness of tiotropium under
real-world conditions.
Methods
The basic idea is to use the strengths of both observa-
tional and RCT data. RCTs are the ideal method for
measuring treatment effects. Randomization reduces
biases by making treatment and control groups “equal
with respect to all features,” except the treatment
assignment [3]. Nevertheless, the population in trials
often does not reflect a real-world population. An
approach to measure the cost-effectiveness for this
population is to apply the relative treatment effect
found in RCTs to the baseline risk for an event calcu-
lated from observational data. As such, the incremental
cost-effectiveness ratio (ICER), which is driven by abso-
lute benefit, will be lower (i.e. more cost-effective) in
subgroups with a higher baseline risk of a certain event
(such as exacerbations and exacerbation-related hospita-
lisations), and vice versa [4]. This is under the assump-
tion that the relative treatment effect is independent
from the baseline risk. In the absence of published evi-
d e n c eo nad i f f e r e n c ei nr e l a t i v et r e a t m e n te f f e c t
between subgroups, this may be seen as a realistic
assumption.
The calculation contains three steps: a) what is the
cost and frequency of events for COPD patients not tak-
ing tiotropium (based on observational data); b) how
many events would have occurred if these patients
would have been treated with tiotropium (applying the
relative treatment effect derived from the RCT on these
observational data); and c) what is the ICER comparing
the incremental costs and benefits with and without tio-
tropium treatment?
Decision model
The analysis is performed from the perspective of the
health care payer, including both costs paid by the stan-
dard health insurance and patient co-payment contribu-
tions. A review on the efficacy/effectiveness of
tiotropium showed no impact of tiotropium on survival
[2]. However, avoiding exacerbations and exacerbation-
related hospitalisation may influence quality of life
(QoL). Therefore, a cost-utility analysis is performed.
There is no evidence that the long-term course of the
disease is altered by using tiotropium in comparison
with its relevant comparators, such as salmeterol. There-
fore, for this chronic disease, a short-term time horizon
of one year is applied. Moreover, one year appears to be
long enough to capture a significant number of impor-
tant clinical endpoints such as exacerbations and exacer-
bation-related hospitalisations, and to capture seasonal
variations. Due to the short time horizon, no discount
rate was applied.
The structure of the model is shown in figure 1. The
disease course of COPD is more complex than this
model shows. However, to calculate an intervention’s
cost-effectiveness, only the difference in (i.e. incremen-
tal) costs and effects are of importance. For example,
since there is no univocal proven impact on mortality,
this event is not taken into account.
Tiotropium study database
Data on health care use, patient characteristics, and
pathology information of tiotropium users was drawn
from two existing data sources: the IMA (Common
Sickness Funds Agency) claims database and the MCD-
HBD (Minimal Clinical Data - Hospital Billing Data)
pathology and claims database of in hospital stays from
the TCT (Technical Cell). The IMA claims database
contains the detailed registration of all ambulatory and
in hospital health care use reimbursed by the Belgian
compulsory health insurance. The TCT MCD-HBD
database contains the detailed registration of both reim-
bursements and ICD9-CM codes of all Belgian in hospi-
tal health care use. IMA claims and patient
characteristics data from 2002 to 2006 for patients for
which the NIHDI code 00470448 (Spiriva, tiotropium)
and corresponding CNK (pharmaceutical product code)
codes indicated a tiotropium delivery between March 1,
2004 and December 31, 2006, was requested. For the
selected patients, all MCD-HBD hospital stay data from
2002 to 2005 were obtained. As such, observational data
one year before and after the first delivery of tiotropium
was gathered. A detailed description of these data
sources and the technicalities of the construction of the
tiotropium study database can be found in the appendix
of the full HTA [2].
In this database, the first delivery of tiotropium to a
patient can fall between March 1, 2004 and December
31, 2005. As a result, the year before the first delivery
can fall between March 1, 2003 and December 31, 2005.
The year after the first delivery can start for some
patients on March 1, 2004 up to December 31, 2005
and end somewhere between March 1, 2005 and
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exacerbations and exacerbation-related hospitalisations
without tiotropium is based on the year before the first
tiotropium delivery. Details on the costs for tiotropium
were based on the first year after the first delivery.
Information on costs for exacerbation-related hospitali-
sations was based on the complete database.
An authorization for the processing and analyses of
this database was obtained from the Belgian Privacy
Commission [5].
Population
The initial database of patients with at least one regis-
tration of tiotropium included 102 796 patients. From
this database, an algorithm was used to select patients
that used tiotropium on a more regular basis (more
than one delivery on separate days, total number of
daily defined dosis (DDDs) ≥ 90 in one year, reimburse-
ment for tiotropium ≥ €120 in one year, DDD ratio ≥
90/365, at least one year of data before and after the
first delivery for tiotropium). 56 321 patients (54.79%)
fulfilled all criteria. The average age is 68.05 years and
66.39% are male. These patients should all have been
diagnosed with COPD since in Belgium reimbursement
of tiotropium is restricted to this indication.
Medication
The costs, including both the NIHDI reimbursement
and patient co-payment, were on average €427.71 for
tiotropium (table 1). The observational database showed
there is no clear indication for a decrease in the use of
other medication when patients started taking tiotro-
pium. Therefore, these costs were left unchanged in the
base case scenario.
Exacerbations
Since no ambulatory clinical data were available, exacer-
bations are defined on the basis of health care resources
use. The proxy used was the delivery of both oral corti-
costeroids and antibiotics within 7 days. As such, the
number of exacerbations was underestimated since in
practice not all exacerbations are treated this way. A
Dutch study found that steroids combined with an anti-
biotic were prescribed in 23% of exacerbations [6]. This
factor was taken into account in our model resulting in
Figure 1 Decision model of tiotropium for the treatment of COPD. (Additional file). exac.: exacerbation. Items shown in grey are not taken
into account.
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year, which was in line with the yearly exacerbation fre-
quency in the UPLIFT trial (0.85 in the placebo group).
The cost per exacerbation was defined theoretically.
The dosis of bronchodilators may be increased and oral
steroids (7-10 days 30-40 mg prednisolone) and antibio-
tics (3-7 days in case of certain symptoms) may be pre-
scribed. For our calculation, the costs for oral steroids
and antibiotics take into account a uniform distribution
on the number of days, i.e. 7-10 days and 3-7 days for
both drugs, respectively. The price for prednisolone was
€31.5 for 20 units of 32 mg, i.e. €1.58 per day. With
respect to antibiotics, a daily cost of €1.13 was taken
into account (amoxicilline (Docamoxi - 500 mg) taken 3
times a day (1500 mg/day) costs €6.02 for 16 units).
One to two visits (uniform distribution) to the general
practitioner (€22.46 per visit) were also added. As a
result, the price for an exacerbation not requiring hospi-
talisation was on average €52.72 (Table 1).
Exacerbation-related hospitalisations
All hospitalisations except for one day admissions for
the selected patients were at our disposal. To calculate
the number of COPD related hospitalisations, only those
stays with ICD-9-CM codes (and subcodes) 491 (chronic
bronchitis), 492 (emphysema) and 496 (COPD, not
otherwise specified) as the primary diagnosis in any hos-
pital ward during the stay were retained.
This resulted in a rate of 0.14 (SD 0.46) hospitalisa-
tions per year (Table 1), comparable to the 0.16 rate in
the placebo arm of the UPLIFT trial.
To calculate the cost of a COPD hospitalisation, an
additional, more stringent, selection criterion was used:
the hospital stay must be spend either in a single hospi-
tal ward, or in two hospital wards of which one was the
intensive care unit. This avoided an impact on hospitali-
sation cost of interventions unrelated to COPD in the
same stay in other hospital wards. The cost was calcu-
lated as the sum of all expenditures available in the
MFG data for the selected stay. In Belgium, hospital per
diem costs are covered by 2 distinct systems of public
health funding. A major part is covered through fixed
monthly hospital payments but these are not registered
in the MFG data. Additional remuneration consists of a
lump sum billed per admission and a lump sum billed
per day of hospital stay, both included in the MFG data.
These lump sums were replaced by the 100% hospital
per diem costs calculated as the actual per diem prices
available per hospital, per year, per semester and per
type of stay (published by NIHDI [7]) multiplied by the
number of invoiced days for the stay. The average
Table 1 Input parameters for the economic evaluation
Input variable Base-case value Range (95% CI) Source
Costs (€)
medication
tiotropium real-world
a 427.71 426.25 429.17 Belgian database
theoretical 621.00 / / BCFI
salmeterol real-world
b 225.46 223.00 227.92 Belgian database
exacerbation theoretical 52.72 41.34 64.48 result 1000 simulations
exac.-rel. hosp. 5617 5555 5680 Belgian database
Utilities
exac.-rel. hosp. QALYgained
c 0.013 0.004 0.019 result 1000 simulations
at admission -0.077 -0.58 0.79 O’Reilly et al.[9]
at discharge 0.58 -0.16 0.98 O’Reilly et al.[9]
LOS (days) 14.18 14.02 14.34 Belgian database
exacerbation QALYgained
c 0.003 0.001 0.005 result 1000 simulations
Events (average per patient)
exacerbations 0.800 0.775 0.826 Belgian database and Roede et al.[6]
exac.-rel. hosp. 0.141 0.137 0.144 Belgian database
Efficacy/effectiveness
exacerbation relative risk
d 0.86 0.81 0.91 Tashkin et al.[8]
exac.-rel. hosp. relative risk
d 0.94 0.82 1.07 Tashkin et al.[8]
BCFI: Belgian Centre for Pharmacotherapeutic Information; LOS: length of stay; NIHDI: National Institute for Health and Disability Insurance; QALY: quality-adjusted
life year
a: based on the first year of tiotropium use
b: based on the year before the first delivery of tiotropium
c: average QALY gained per event avoided
d: using the published 95%CI to define our distribution results in the following mean values in the model: 85.85% instead of 86% and 93.67% instead of 94%.
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related hospitalisation cost was €5617 (SD 6023).
Treatment effect
In October 2008, results of the UPLIFT trial have been
published. In this randomized, double-blind trial, 4 years
of tiotropium treatment was compared with placebo in
patients with COPD who were permitted to use all
respiratory medications except inhaled anticholinergic
drugs. The patients were at least 40 years of age, with a
post-bronchodilator FEV1 of 70% or less than the pre-
dicted value and a ratio of FEV1/FVC of 70% or less. In
this very large trial, 2987 and 3006 patients were ran-
domly assigned to the tiotropium and placebo group,
respectively [8]. The hazard ratio for COPD exacerba-
tions was 0.86 (95% CI: 0.81 - 0.91; p-value <0.001). For
exacerbations leading to hospitalisations this was 0.94
(95% CI: 0.82 - 1.07; p-value = 0.34).
In the tiotropium study database, it was observed that
there was no reduction in the use of other medication
after the first delivery of tiotropium. For example, in
both the year before and after the first tiotropium deliv-
ery, 80% of patients purchased at least one package of
long-acting beta-agonists, salmeterol or formoterol,
either in individual formulation or in combination with
an inhaled corticosteroid. In other words, in the real
world, tiotropium does not always replace the other
long-acting bronchodilators and the comparator is a
combination of other drugs. Similarly, in the UPLIFT
trial, other drugs were taken and a long-acting inhaled
b2-agonist was used in 60.1% of both treatment arms
and tiotropium was added in one treatment arm [8].
Therefore, both because of its size and because it seems
to correspond to what happens in reality, the treatment
effects and the surrounding uncertainty from the
UPLIFT trial are taken into account to calculate the
real-world cost-effectiveness of tiotropium.
Utilities
Tiotropium may avoid exacerbations and exacerbation-
related hospitalisations. Next to changes in costs, this
also entails changes in utilities. Therefore, for both
exacerbations and exacerbation-related hospitalisations
QoL data were gathered. One article explicitly stated
general QoL outcomes associated with COPD exacerba-
tion managed in a UK-based hospital, using the EQ-5 D
questionnaire, including 149 patients representing 222
admissions to hospital [9]. At admission, the mean uti-
lity (-0.077, SD: 0.397) indicated great impairment, with
61% of patients having a negative utility value represent-
ing a health state equivalent to ‘worse than death’. Great
improvements were reported during admission and at
discharge, where the mean utility value was increased to
0.576 (SD: 0.317). This deterioration and improvement
in QoL was included in our model for exacerbation-
related hospitalisations. A correlation of 0.9 was imple-
mented between the value at admission and discharge to
avoid increases of more than 1.1584 (i.e. the maximum
difference according to the Flemish EQ-5 D utility scale)
in our probabilistic model.
No studies were identified reporting changes in QoL
during exacerbations measured with a generic QoL
instrument. Several studies made assumptions on the
QoL deterioration. A reduction of 15% in QoL for one
month after a (moderate) exacerbation and 50% or 70%
for a severe exacerbation (requiring hospitalisation) was
assumed, [10-13] or a relative ratio of 3.33 or 4.67. In
our model, the average relative ratio of 4 was applied on
the reduction in QoL for an exacerbation-related hospi-
talisation, with a minimum of 3.33 and a maximum of
4.67 (uniform distribution).
Scenario analysis
Next to the base case, two scenarios are elaborated. A
first scenario incorporated the theoretical yearly cost for
tiotropium (€621) and excluded the observed expendi-
tures for salmeterol (on average €225.46), reflecting
100% tiotropium compliant use r st h a td i dn o tt a k es a l -
meterol anymore. In a second scenario, the ICER was
calculated depending on the initial number (i.e. without
tiotropium) of exacerbations and hospitalisations. Details
and results of other scenario analyses can be found in
the full HTA report [2].
Probabilistic modelling
To capture parameter uncertainty, input variables in our
model are probabilistic values. The choice of distribu-
tion depends on the characteristics of the input vari-
ables. Due to the central limit theorem, cost parameters
retrieved from the large tiotropium study database were
sampled from a normal distribution with the appropriate
confidence interval around the mean (table 1). Uniform
distributions were included were we had no idea of the
distribution (e.g. in our theoretically calculated exacer-
bation cost). The beta distribution, which is constrained
on the interval 0-1, is the ideal distribution for QoL
values. Since the study of O’Reilly et al [9]. provided
QoL data during an exacerbation-related hospitalisation
with negative values, an adjusted beta distribution with
the reported minimum value of -0.59 and a maximum
of 1 was applied. Finally, the relative risk parameters are
modelled using the lognormal distribution, reflecting the
published mean values and 95% CI. 1000 Latin hyper-
cube simulations were generated in MicroSoft Excel
using the @Risk (Palisade Corporation) add-in program.
Following the Belgian pharmacoeconomic guidelines,
the central estimate of the ICER results directly from
the probabilistic sensitivity analysis as the mean of the
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the ratio of the mean incremental cost and mean incre-
mental effect, which is the deterministic version of the
ICER. A deterministic ICER is presented if the Latin
Hypercube simulations fall in different quadrants of the
cost-effectiveness plane [14].
Results
Base case scenario
The mean incremental cost is €373 per patient (95% CI
279 - 475). This incremental cost is composed of the
following three elements: incremental cost medication:
€427.71 (95% CI 426.25 - 429.17), incremental cost
related to hospitalisations: -€48.26 (95% CI -143.11 -
55.61), and the incremental cost related to exacerba-
tions: -5.95 (95% CI -8.76 - -3.56). The UPLIFT non-sig-
nificant treatment effect on hospitalisations and the
significant treatment effect on exacerbations are
reflected in these confidence intervals. The incremental
benefit expressed as quality-adjusted life years (QALY)
gained are on average 0.00048 (95% CI 0.00009 -
0.00092). This is relatively low due to the combination
of the following factors: a) a low number of hospitalisa-
tions without tiotropium treatment (on average 0.14/
year), b) a non-significant treatment effect (on average
0.94) with respect to avoiding exacerbation-related hos-
pitalisations, and c) the relatively short duration that
this event influences QoL. In combination with the non-
negligible incremental costs, this results in an ICER of
€1 244 023 (95% CI 328 571 - 4 712 704) per QALY
gained. Results are presented on the cost-effectiveness
plane (Figure 2) and cost-effectiveness acceptability
curve (Figure 3). The latter shows that the treatment
can only be considered cost effective at relatively very
high willingness-to-pay values. The results are most sen-
sitive to the treatment effect on hospitalisations (correla-
tion coefficient 0.671).
Scenario analyses
In the scenario with 100% compliant tiotropium users
which stopped taking salmeterol, the incremental cost
decreases to €341 (95% CI 246 - 445). In combination
with the same incremental benefit, this results in an
ICER of €1 142 478 (95% CI 295 004 - 4 396 273) per
QALY gained.
Table 2 presents the cost-effectiveness of tiotropium
depending on the initial number of exacerbations and/
or hospitalisations. It shows that the number of hospita-
lisations in particular determines tiotropium’s cost-effec-
tiveness. Even with 10 exacerbations without tiotropium,
the average ICER is above €100 000 per QALY gained if
the patient has no hospitalisation without tiotropium.
Based on our large observational database, 89% of the
patients (i.e. 50 156 patients) was not hospitalised for
COPD in the year before the first tiotropium delivery.
For patients who would not have been hospitalised with-
out tiotropium, there is not much to gain by treating
them with tiotropium. Only 2.2% had two or more
COPD-related hospitalisations prior to tiotropium
treatment.
Discussion
A disadvantage of our database is that no parameter was
present indicating the COPD stage. As a result, no sub-
group analyses could be made according to these stages.
In our approach, the population was initially analysed as
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Figure 2 The cost-effectiveness plane. (Additional file). QALY: quality-adjusted life year.
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In subgroup analyses, the population was divided
depending on the number of hospitalisations related to
exacerbations (i.e. one, two, three or more exacerbation-
related hospitalisations) in combination with the num-
ber of exacerbations. These subgroup analyses showed
that, in the first place, for a selected group of patients
with a relative high base risk on events, the results were
more cost effective. On the other hand, it also showed
that this is only a minority of the population taking tio-
tropium on a regular basis. The largest group of patients
did not experience any exacerbation or hospitalisation.
For this group of patients no events can be avoided
because they do not occur without taking tiotropium,
no QoL can be gained, no costs will be saved, and tio-
tropium would only induce higher costs.
As mentioned by Drummond, “The assumption of
constant relative effects being applied to subgroup-spe-
cific baseline event rates is common in cost-effectiveness
model.” [ 4 ]Ag e n e r a lc r i t i c i s m si st h a ti tm a yb eq u e s -
tionable whether the relative treatment effect is inde-
pendent from the baseline risk since subgroup analysis
often show the opposite. On the other hand, caution is
needed when drawing conclusions from subgroup find-
ings [15]. It is generally recognized that subgroup ana-
lyses can produce spurious results [16]. Some authors
even argued that “the overall ‘average’ result of a rando-
mised clinical trial is usually a more reliable estimate of
treatment effect in the various subgroups examined than
are the observed effects in individual subgroups” [17].
Furthermore, even if the relative treatment effect would
be higher in a specific subgroup, than still the absolute
gain (which determines the cost-effectiveness) would be
limited due to the low baseline risk for events without
tiotropium treatment occurring in our real-world
population.
Our health technology assessment included a systema-
tic review of the economic literature. Details of the
search strategy are available in the full HTA report [2].
Eight full economic evaluations of tiotropium were iden-
tified, all published after 2004. Analyses were performed
for the Netherlands, [12,18] Canada, [12,19] Switzerland,
[20] Greece, [11] Spain, [13] and the US [21,22]. Two
studies were trial-based economic evaluations [18,19].
The US studies were deterministic [21] or probabilistic
[22] simulations using aggregated data depicting a typi-
cal COPD patient. The remaining four studies were
Markov model-based economic evaluations, all built on
an initial model developed by Oostenbrink et al [12]. All
studies limited their time horizon to one year, with
exception of one model-based evaluation using a 5-year
time horizon [13]. Surrogate outcome measures of the
drugs’ clinical action were used in cost-effectiveness
analyses: exacerbation-free months gained [13] or
exacerbations avoided [11,12,18-20,22]. These outcomes
are rather difficult to interpret by decision makers, e.g.
being not comparable with results of studies in other
indications.
Four studies compared tiotropium with salmeterol
[11-13,20]. The mean incremental outcomes in these
analyses (whether QALYs gained, exacerbations avoided
or exacerbation-free months gained) were associated
with large 95% confidence intervals crossing zero
[11-13]. One study found tiotropium to be dominant,
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Figure 3 The cost-effectiveness acceptability curve. (Additional file). QALY: quality-adjusted life year.
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cally not including uncertainty around the treatment
effect. Two studies found that there was almost neutral-
ity between the two alternatives in terms of incremental
costs and QALYs, as the dots simulated were almost
evenly scattered around the four quadrants of the cost-
effectiveness plane [11,12]. In the cost-utility analysis
with a 5-year-time horizon, approximately 80% of the
simulations were in the right quadrants of the cost-
effectiveness plane. The gain in QALYs remained how-
ever small (0.14) and non-significant (95% CI: -0.16-
0.49). Based on the ratio of the mean incremental costs
to the mean incremental QALYs, they found a cost-
effectiveness ratio of €4118 per QALY gained [13]. We
discuss some differences between these analyses.
One of the strengths of our evaluation is that it con-
siders patients that use tiotropium in their everyday life.
In contrast, populations considered in previous analyses
were more selective. All previous analyses, with the
exception of one, [22] excluded patients with mild
COPD. Nevertheless, these patients are also included in
the Belgian reimbursement modalities for tiotropium.
This can be very determining for the results of an eco-
nomic evaluation. The base risk for certain events may
Table 2 IC, IE and ICERs depending on the initial number of hospitalisations and exacerbations
prior n° of
exac.
prior number (n°) of hospitalisations
012
IC IE ICER IC IE ICER* IC IE ICER*
0 428 0.0000 dominated 84 0.0008 107666 -259 0.0016 cost
saving
426 429 0.0000 0.0000 -581 819 -0.0009 0.0027 -1589 1211 -0.0017 0.0054
1 420 0.0005 1265951 77 0.0012 62094 -266 0.0020 cost
saving
416 424 0.0001 0.0008 497057 4154369 -590 812 -0.0004 0.0033 -1599 1204 -0.0013 0.0061
2 413 0.0009 622357 70 0.0017 41019 -274 0.0025 cost
saving
406 419 0.0002 0.0017 242740 2049176 -599 805 0.0000 0.0039 -1608 1196 -0.0008 0.0066
3 405 0.0014 407826 62 0.0022 28873 -281 0.0029 cost
saving
395 415 0.0003 0.0025 158255 1338516 -608 797 0.0002 0.0046 -1617 1189 -0.0003 0.0072
4 398 0.0018 300561 55 0.0026 20974 -289 0.0034 cost
saving
384 410 0.0004 0.0034 116258 983186 -618 790 0.0003 0.0053 -1626 1182 0.0000 0.0077
5 391 0.0023 236201 47 0.0031 15425 -296 0.0038 cost
saving
374 406 0.0005 0.0042 90683 769988 -627 780 0.0005 0.0061 -1635 1175 0.0003 0.0085
6 383 0.0027 193295 40 0.0035 11314 -303 0.0043 cost
saving
363 401 0.0006 0.0050 74097 627857 -634 770 0.0007 0.0068 -1645 1167 0.0004 0.0092
7 376 0.0032 162648 32 0.0040 8146 -311 0.0048 cost
saving
352 397 0.0007 0.0059 62023 529076 -641 760 0.0008 0.0076 -1654 1160 0.0006 0.0099
8 368 0.0036 139662 25 0.0044 5630 -318 0.0052 cost
saving
341 392 0.0008 0.0067 52879 456718 -650 750 0.0010 0.0084 -1663 1153 0.0007 0.0106
9 361 0.0041 121784 18 0.0049 3583 -326 0.0057 cost
saving
330 388 0.0009 0.0075 45609 400440 -659 740 0.0011 0.0092 -1672 1143 0.0008 0.0114
10 353 0.0046 107482 10 0.0053 1885 -333 0.0061 cost
saving
319 383 0.0010 0.0084 39741 355417 -667 730 0.0012 0.0100 -1681 1133 0.0010 0.0122
Exac. = exacerbations
IC: incremental cost (expressed in euro); IE: incremental effect (expressed in quality-adjusted life years (QALY) gained); ICER: incremental cost-effectiveness ratio
(expressed in cost per QALY gained). In every cell, the mean value and the lower (2.5%) and upper (97.5%) limits of the interval are mentioned.
* the ICERs of the probabilistic model are not mentioned since simulation results are spread over several quadrants of the cost-effectiveness plane. As an
alternative (in italics), the ICER calculated by dividing the mean incremental cost by the mean incremental benefit is presented.
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selective population. It is the combination of this base
risk and the relative treatment effect that determines the
absolute reduction in events, which determines the
intervention’s cost effectiveness.
Next, there are differences in applied treatment effects.
Studies comparing tiotropium with salmeterol relied on
the trial results published by Brusasco et al [23]. At that
time, results of the UPLIFT trial were not published yet.
These trials are not designed to detect a difference in
exacerbation-related hospitalisations. It is therefore
important to take into account the uncertainty around
these estimations. The mean treatment effect in the
UPLIFT trial is 0.86 (95% CI 0.81 - 0.91, p-value <0.001)
for exacerbations and 0.94 (95% CI 0.82 - 1.07, p-value
= 0.34) for exacerbations leading to hospitalisations. The
mean treatment effect based on the Brusasco trial is
similar for exacerbations, i.e. 0.87 (p-value = 0.22), but
much more favourable for hospitalisations, being 0.59
(non-significant but no p-value published). Both esti-
mates are surrounded by much uncertainty. Further-
more, it should be remarked that a critical review of the
literature identified the presence of publication bias [2].
A second trial [24] also reported non-significant p-
values for the difference in exacerbation and hospitalisa-
tion frequencies. However, no exact results (even no
mean values) were provided and results could therefore
not be included in a meta-analysis.
There were also large cost differences between the
identified studies, both with respect to the cost of medi-
cation, treatment of exacerbations and cost of hospitali-
sations. For example, a non-severe exacerbation costs
between €47 in Canada [12] against nearly €1000 in
Greece [11]. Similarly, a severe exacerbation costs €2660
in Spain [13] against €4400 in Greece, [11] and even
over €4600 in the US [22]. In our study the cost for an
exacerbation not requiring hospitalisation was on aver-
age €52.72 and the COPD-related hospitalisation cost
was €5617. In general, the higher these event-related
costs (which are context specific), the more favourable
study results are for tiotropium. Of course, the impact
depends on the combination of the baseline risk for an
event, the treatment effect and its costs.
Most economic evaluations used a 1-year timeframe
and assumed tiotropium had no influence on mortality.
Only one analysis took a 5-year time horizon reflecting
the progressive nature of COPD [13]. The authors note
that no differences between treatments (tiotropium, sal-
meterol or ipratropium) in terms of mortality risk were
assumed. Also the costs per disease severity state and
per severe or non-severe exacerbation were mentioned
to be equal across treatment groups. In their discussion,
the authors repeat that the difference between the three
treatment groups in terms of QALYs were small, which
was expected because treatments do not directly affect
survival [13]. However, in this analysis, mortality is
influenced when comparing the three treatment arms
due to different transition probabilities between the dis-
ease states for the alternative treatments. In other
words, the chance of dying when a patient is in a certain
disease state is equal over the three groups with the
highest probability in the very severe disease state.
Nonetheless, the transition probability to go to the more
severe disease states was modelled to be higher for sal-
meterol and ipratropium. As a result, this model impli-
cated an implicit effect on mortality. Replicating the
model with the same probabilities as in the published
paper, the 5-year mortality was about 15% with tiotro-
p i u ma n da b o u t2 0 %w i t hs a l m e t e r o la n di p r a t r o p i u m .
Absence of evidence is not evidence of absence. How-
ever, based on currently available evidence, indirectly
modelling a relatively large impact on mortality can be
considered as a rather optimistic scenario.
Impact on events which may influence QoL is one of
the main drivers of results. Unfortunately, accurate uti-
lity (or disutility) scores for events on which tiotropium
may have an impact, i.e. exacerbations and exacerba-
tion-related hospitalizations, are still lacking. We
included data reflecting on the impact on QoL during
hospitalisation. It was previously remarked that low
values reported during the stay in hospital partly consti-
tute an effect of the exacerbation and partly of the hos-
pitalisation. The improving figures after returning home
are probably due to a change in both medical status and
environment [25]. Especially the fact of being hospita-
lised may influence QoL. However, we currently do not
know whether further improvements are observed after-
wards in real life. Three studies including EQ-5 D health
states estimated that utility values would reduce by 15%
[26] in case of non-severe exacerbation, and by 50% [27]
in case of severe exacerbation [11-13]. Nevertheless, the
referenced papers to support these figures do not men-
tion such data. It would be interesting if researchers try
to measure the impact of these events on QoL (in com-
plement to measuring QoL on pre-specified points in
time, since these events may occur in between). This
would enable a more evidence-based calculation of
impact on QALYs [28].
Conclusion
This is the first economic evaluation that tries to calcu-
late tiotropium’s cost-effectiveness for a population trea-
ted in every-day practice. This is done by combining
three elements in a model: a) the number of events
without tiotropium (the baseline risk); b) tiotropium’s
treatment effect on these events; and c) the changes in
QoL by avoiding an event. For the latter, assumptions
had to be made due to a lack of evidence. Further
Neyt et al. BMC Pulmonary Medicine 2010, 10:47
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QoL (measured with a generic instrument useful for
economic evaluations) would be interesting. For the
other two elements, the published treatment effects
from the UPLIFT trial were applied on the baseline risk
for exacerbations and exacerbation-related hospitalisa-
tions observed in a large Belgian database. The cost-
effectiveness of tiotropium was unfavourable due to the
low average of hospitalisations with standard care but
without tiotropium treatment (almost 90% did not
experience an exacerbation-related hospitalisation). As a
result, treating this part of the population with tiotro-
pium mainly results in extra costs without benefits.
From a medical point of view, tiotropium earns its
place in the treatment of COPD. As shown in a sys-
tematic review of the literature, tiotropium was found to
have statistically significant effects compared to placebo
and ipratropium, but not compared to salmeterol [2].
Furthermore, the GOLD (Global Initiative for Chronic
Obstructive Lung Disease) guideline mentions that regu-
lar treatment with long-acting bronchodilators is more
effective and convenient than treatment with short-act-
ing bronchodilators. The choice between b2-agonists,
anticholinergics, methylxanthines, or combination ther-
apy depends on availability and individual response in
terms of symptom relief and side effects. However, there
is insufficient evidence to favour one long-acting
bronchodilator over another [29].
To date, tiotropium has not clearly demonstrated an
important effect on QALYs nor generated large cost
savings by avoiding COPD related events in comparison
to standard treatment (real world situation) or in com-
parison with salmeterol. Since tiotropium does not per-
form worse but also not much better than its
comparator on patient-relevant outcomes, the higher
price of tiotropium can be questioned from a payer’s
perspective. Price negotiations could be started in a revi-
sion procedure of the reimbursement modalities. If tio-
tropium’s price would for example be reduced to €31.24
for 30 units, i.e. the price in Belgium for the long-acting
bronchodilator salmeterol, than the budget impact for
both the NIHDI and the patient’s co-payment, based on
2007 data, would decrease to about €16 million, or a
cost saving of more than €10 million a year. These
resources could then be invested more efficiently. With
current pressure on budgets, these efficiency considera-
tions should not be neglected in resource allocation
decisions.
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